Melatonin down-regulates HIF-1α expression through inhibition of protein translation in prostate cancer cells

Journal of Pineal Research

Volumn 46, Issue 4, 2009, Pages 415-421

  Park, Jong Wook ^a   Hwang, Mi Sun ^a   Suh, Seong Il ^a   Baek, Won Ki ^a  

^a Keimyung University   (South Korea)

Author keywords

Angiogenesis; HIF 1 ; Melatonin; P70S6K; Prostate cancer; Translation; Vascular endothelial cell growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELATONIN; MESSENGER RNA; S6 KINASE; VASCULOTROPIN;

ARTICLE; CELL HYPOXIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

CELL LINE, TUMOR; DATA INTERPRETATION, STATISTICAL; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MELATONIN; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA STABILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64649100878     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2009.00678.x     Document Type: Article

References (42)

1. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991 12 : 151 180.
2. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experentia 1993 49 : 654 664.
3. Maldonado MD, Murillo-Cabezas F, Terron MP et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 2007 42 : 1 11.
4. Tengattini S, Reiter RJ, Tan DX et al. Cardiovascular disease: protective effects of melatonin. J Pineal Res 2008 44 : 16 25.
5. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008 45 : 235 246.
6. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008 44 : 26 40.
7. Cervantes M, Morali G, Letechipia-Vallejo G. Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res 2008 45 : 1 7.
8. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004 37 : 213 214.
9. Shiu SYW. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res 2007 43 : 1 9.
10. Vijayalaxmi, Thomas CR Jr, Reiter RJ et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002 20 : 2575 2601.
11. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988 48 : 6121 6126.
12. Cos S, Fernandez R, Guezmes A et al. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998 58 : 4383 4390.
13. Marelli MM, Limonta P, Maggi R et al. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 2000 45 : 238 244.
14. Blask DE, Sauer LA, Dauchy RT et al. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999 59 : 4693 4701.
15. Xi SC, Siu SW, Fong SW et al. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 2001 46 : 52 61.
16. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002 8 : S62 S67.
17. 2 tension. Proc Natl Acad Sci U S A 1995 92 : 5510 5514.
18. 2 sensing. Science 2001 292 : 464 468.
19. Masson N, Willam C, Maxwell PH et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001 20 : 5197 5206.
20. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003 3 : 721 732.
21. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007 85 : 1301 1307.
22. Fukuda R, Hirota K, Fan F et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002 277 : 38205 38211.
23. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000 60 : 1541 1545.
24. 2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003 63 : 2330 2334.
25. 2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002 277 : 50081 50086.
26. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999 59 : 5830 5835.
27. Lissoni P, Rovelli F, Malugani F et al. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 2001 22 : 45 47.
28. Cui P, Luo Z, Zhang H et al. Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J Pineal Res 2006 41 : 358 362.
29. 2 in cultured cancer cells. J Pineal Res 2008 44 : 121 126.
30. Oh HJ, Lee JS, Song DK et al. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun 2007 360 : 840 845.
31. Metzen E, Zhou J, Jelkmann W et al. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol Biol Cell 2003 14 : 3470 3481.
32. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002 22 : 7004 7014.
33. Laughner E, Taghavi P, Chiles K et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001 21 : 3995 4004.
34. Allegra M, Reiter RJ, Tan DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003 34 : 1 10.
35. Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
36. Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 2007 42 : 386 393.
37. Blask DE, Dauchy RT, Sauer LA et al. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 2004 25 : 951 960.
38. Leon-Blanco MM, Guerrero JM, Reiter RJ et al. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 2003 35 : 204 211.
39. Kilic E, Kilic U, Reiter RJ et al. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 2004 37 : 247 251.
40. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004 4 : 335 348.
41. Jefferies HB, Fumagalli S, Dennis PB et al. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997 16 : 3693 3704.
42. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006 12 : 122 127.